Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
Sponsor: University of Colorado, Denver
Summary
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Official title: The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2019-02-01
Completion Date
2024-06-10
Last Updated
2026-07-01
Healthy Volunteers
No
Conditions
Interventions
Acthar
patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
Locations (1)
Medstar Georgetown Transplant Institute
Washington D.C., District of Columbia, United States